New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
07:33 EDTVPHMViroPharma's Cinryze prophylaxis study showed safety data of escalating doses
ViroPharma announced important data from an open-label, multicenter study to assess the safety, tolerability, and treatment effect of escalating doses of C1 INH-nf in patients with HAE who were not adequately controlled with 1000 U every 3 or 4 days. The results of this study were presented at the 2012 annual meeting of the American College of Allergy, Asthma and Immunology, or ACAAI, in Anaheim, California. The data provide evidence for the safety profile of Cinryze, or C1 esterase inhibitor [human], at doses up to 2500 units in patients with hereditary angioedema, or HAE. The study was a post marketing FDA requirement to assess the safety and tolerability of escalating doses of Cinryze, with specific interest in thrombogenicity and immunogenicity.
News For VPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for VPHM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use